Sample size considerations for trials using cerebral white matter hyperintensity progression as an intermediate outcome at 1 year after mild stroke: results of a prospective cohort study-Reference-Cited by-同舟云学术

Sample size considerations for trials using cerebral white matter hyperintensity progression as an intermediate outcome at 1 year after mild stroke: results of a prospective cohort study

Published:2017-02-21 Issue:1 Volume:18 Page:
ISSN:1745-6215
Container-title:Trials
language:en
Short-container-title:Trials

Author:

Chappell Francesca M.,del Carmen Valdés Hernández Maria,Makin Stephen D.,Shuler Kirsten,Sakka Eleni,Dennis Martin S.,Armitage Paul A.,Muñoz Maniega Susana,Wardlaw Joanna M.

Funder

Wellcome Trust

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Medicine (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1186/s13063-017-1825-7.pdf

Reference45 articles.

1. Kim TW, Kim YH, Kim KH, Chang WH. White matter hyperintensities and cognitive dysfunction in patients with infratentorial stroke. Ann Rehabil Med. 2014;38(5):620–7.

2. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003;34(5):1126–9.

3. Kim YJ, Kwon HK, Lee JM, Kim YJ, Kim HJ, Jung NY, et al. White matter microstructural changes in pure Alzheimer’s disease and subcortical vascular dementia. Eur J Neurol. 2015;22(4):709–16.